Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Adjuvant Therapy In Uterine Sarcomas

Related Books

Free with a 30 day trial from Scribd

See all

Related Audiobooks

Free with a 30 day trial from Scribd

See all
  • Be the first to comment

Adjuvant Therapy In Uterine Sarcomas

  1. 1. ADJUVANT THERAPY IN UTERINE SARCOMAS Dr. T. Sujit A M O ( Radiation Oncology ) Valavadi Narayanaswami Cancer Centre, G.Kuppuswamy Naidu MemorialHospital, Coimbatore - 641037, Tamilnadu, India May 2007
  2. 2. PROGNOSTIC FACTORS <ul><li>LEIOMYOSARCOMAS </li></ul><ul><ul><li>Mitotic index : 10 -20 / ten HPF  61 % failure rate </li></ul></ul><ul><ul><ul><ul><ul><li>> 20 / ten HPF  79 % failure rate </li></ul></ul></ul></ul></ul><ul><li>MALIGNANT MIXED MULLERIAN TUMORS </li></ul><ul><ul><li>Adnexal spread , Lymph node mets </li></ul></ul><ul><ul><li>Histologic cell type ( Homologous Vs Heterologous ) </li></ul></ul><ul><ul><li>Grade </li></ul></ul>
  3. 3. PATTERNS OF FAILURE <ul><li>LMS : Majority of the recurrence is as distant metastasis </li></ul><ul><ul><li>28% - abdomino-pelvic recurrence </li></ul></ul><ul><ul><li>49% distant mets. </li></ul></ul><ul><ul><ul><li>Pelvic RT offers very little potential gain </li></ul></ul></ul><ul><li>MMMT : Pelvic recurrence rates are higher compared to distant mets </li></ul><ul><ul><li>56% pelvic recurrence </li></ul></ul><ul><ul><li>45% distant mets </li></ul></ul><ul><ul><ul><li>Implies surgery alone is not enough to achieve local control. </li></ul></ul></ul>
  4. 4. ADJUVANT MANAGEMENT <ul><li>Stage I & II – HGUD, LMS, Carcinosarcoma </li></ul><ul><ul><li>Pelvic RT ± Brachytherapy ± Chemotherapy </li></ul></ul><ul><li>Stage III A, III B - HGUD, LMS, Carcinosarcoma </li></ul><ul><ul><li>Pelvic RT ± Brachytherapy ± Chemotherapy </li></ul></ul><ul><ul><li>Abdomino-pelvic RT ( except LMS ) </li></ul></ul><ul><li>Stage III A & III B – ESS </li></ul><ul><ul><li>Hormone therapy ± Pelvic RT </li></ul></ul>
  5. 5. ADJUVANT MANAGEMENT <ul><li>Stage III C - HGUD, LMS, Carcinosarcoma </li></ul>PALN + ve PALN - ve Consider Pelvic RT and/or Vaginal brachytherapy and/or Chemotherapy Consider whole abdominopelvic RT ( except LMS ) Chemo Chest CT ± biopsy scalene nodes Whole abdominopelvic RT or Pelvic and para-aortic RT or Chemotherapy or - VE + VE
  6. 6. ADJUVANT MANAGEMENT <ul><li>Stage IV A – ESS, HGUD, LMS, Carcinosarcoma </li></ul><ul><ul><li>RT </li></ul></ul><ul><ul><li>and/or </li></ul></ul><ul><ul><li>Chemotherapy </li></ul></ul><ul><ul><li>or </li></ul></ul><ul><ul><li>Hormone therapy </li></ul></ul><ul><li>Stage IV B – ESS </li></ul><ul><ul><li>Hormone Therapy </li></ul></ul><ul><li>Stage IV B - HGUD, LMS, Carcinosarcoma </li></ul><ul><ul><li>Chemotherapy </li></ul></ul>
  7. 7. RADIOTHERAPY <ul><li>ADJUVANT RT : </li></ul><ul><li>~ NO RANDOMISED STUDIES </li></ul><ul><li>~ Some studies quote an improvement in pelvic control, especially for carcinosarcomas . * </li></ul><ul><li>~ Recent trials –  OS in stage I C.  </li></ul><ul><li>~ EBRT – 50 Gy / 5 weeks. </li></ul><ul><li>RADICAL RT : </li></ul><ul><li>~ Medically inoperable patients </li></ul><ul><li>~ EBRT 50 Gy + Brachytherapy </li></ul><ul><li>Gerszten K, Faul C, Kounelis S, et al. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus . Gynecol Oncol 1998 </li></ul><ul><li>Tinkler SD, Cowie VJ. Uterine sarcomas: a review of the Edinburgh experience from 1974 to 1992. Br J Radiol 1993 </li></ul><ul><li>Lee CM, Szabo A, Shrieve DC, et al. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial </li></ul><ul><li>adenocarcinoma. JAMA 2006;295:389-397. </li></ul>
  8. 8. E B R T <ul><li>PELVIC RT </li></ul>
  9. 9. BRACHYTHERAPY NORMAN SIMON APPLICATORS
  10. 10. BRACHYTHERAPY <ul><li>ROTTE TWO CHANNEL APPLICATOR ( NUCLETRON ) </li></ul>
  11. 11. POST – OP BRACHYTHERAPY <ul><li>VAGINAL CYLINDERS </li></ul>AFTER 45 – 50 Gy EBRT: 5 -6 Gy x 3 fractions for HDR or 15 Gy in a single fraction for LDR
  12. 12. CHEMOTHERAPY <ul><li>Single agent chemotherapy: </li></ul><ul><ul><li>MMMT: </li></ul></ul><ul><ul><ul><li>Ifosfamide - 1.5 g/m2/d for 5 days </li></ul></ul></ul><ul><ul><ul><li>Cisplatin - cisplatin, 50 mg/m2 </li></ul></ul></ul><ul><ul><li>LMS: </li></ul></ul><ul><ul><ul><li>Doxorubicin ( Adriamycin ) - 50–90 mg/m2 q3wk </li></ul></ul></ul><ul><li>Combination therapy : </li></ul><ul><ul><li>MMMT: </li></ul></ul><ul><ul><ul><li>MAID – Mesna , Adriamycin, Ifosfamide, Dacarbazine </li></ul></ul></ul><ul><ul><ul><li>Doxorubicin + DTIC </li></ul></ul></ul><ul><ul><ul><li>Ifosfamide + Cisplatin </li></ul></ul></ul><ul><ul><li>LMS </li></ul></ul><ul><ul><ul><li>Gemcitabine + Taxanes ( Paclitaxel , Docetaxel ) </li></ul></ul></ul>
  13. 13. HORMONE THERAPY <ul><li>Response to hormonal manipulation is seen in low grade ESS </li></ul><ul><ul><ul><ul><li>Megestrol acetate </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Medroxyprogesterone acetate </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Tamoxifen </li></ul></ul></ul></ul><ul><ul><ul><ul><li>GnRH analogs </li></ul></ul></ul></ul>
  14. 14. T h a n k y o u

×